Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The COVID-19 pandemic has highlighted the importance of vaccines in controlling the epidemic in sub-Saharan Africa and a renewed interest in vaccine research and development across the country.
Read Full NewsFor men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.
Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.
Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.
1.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
2.
Extracellular matrix pathway emerges as treatment target for pediatric cancer
3.
BTK Inhibitor Active in Half of Patients With Richter Transformation
4.
Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia
5.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
1.
Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields
2.
Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"
3.
Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development
4.
Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation
5.
Understanding Hemosiderosis: Causes, Symptoms, and Treatment Options
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
5.
Evidence-Based Oncology
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge